Meagher, M. F. Et Al. 2024. Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy. European Urology Open Science , vol.63 , 71-80.

Meagher, M. F., Minervini, A., Mir, M. C., Cerrato, C., Rebez, G., Autorino, R., ... Hampton, L.(2024). Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy. European Urology Open Science , vol.63, 71-80.

Meagher, Margaret Et Al. "Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy," European Urology Open Science , vol.63, 71-80, 2024

Meagher, Margaret F. Et Al. "Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy." European Urology Open Science , vol.63, pp.71-80, 2024

Meagher, M. F. Et Al. (2024) . "Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy." European Urology Open Science , vol.63, pp.71-80.

@article{article, author={Margaret F. Meagher Et Al. }, title={Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy}, journal={European Urology Open Science}, year=2024, pages={71-80} }